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Abstract The excitatory effect of presynaptically released
glutamate is tightly regulated and terminated by high affinity
sodium-dependent glutamate transporters. The regulation of the
glial glutamate transporter GLT-1 is potentially important in
synaptic modulation. Using astroglial cultures prepared from the
rat cerebral cortex, we found that the N-opioid receptor agonist
[D-pen2,D-pen5]-enkephalin decreases and glutamate increases
the expression of the GLT-1 transporter mRNA. Corresponding
changes in the uptake kinetics were found after incubation for 48
h with the respective agonists when glial glutamate uptake was
measured in primary astroglial cultures. The data suggest that
long-term receptor activation induces alterations in glial
glutamate uptake properties.
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1. Introduction
Glutamate transport is coupled to the co-transport of Na
and the counter transport of K, with no dependence on Cl3.
Glutamate has an intimate coupling to the extracellular po-
tassium levels and the membrane potential. For each gluta-
mate anion transported into the cell, three Na (or two Na
and one H) ions are co-transported into the cell, and one K
ion is transported out of the cell [1].
Three brain glutamate transporter cDNAs have so far been
isolated: excitatory amino acid carrier (EAAC1) [2], gluta-
mate/aspartate transporter (GLAST) [3] and glutamate trans-
porter GLT-1 [4]. EAAC1 has been reported to be localized to
neurons [2], and GLT-1 and GLAST are expressed in glial
cells [3,5]. Astrocytes are active in the maintenance of the
physiological conditions in and around the synaptic cleft.
The astroglial expression of uptake carriers for amino acid
neurotransmitters is well documented [6^10]. Glial cells ex-
press receptors for a number of neuromodulators, including
glutamate and opioid receptors [11^16].
One of the most abundant transmitters is the excitatory
amino acid glutamate. This transmitter is released from nerve
terminals. Glutamate di¡uses and activates postsynaptic re-
ceptors. Thereafter, the transmitter is taken up into nerve
terminals and astroglial cells [17]. The synaptic activation is
thereby terminated. Furthermore, it has recently been shown
that transmitter uptake in astrocytes is acutely regulated by
surface receptors in both a stimulatory and an inhibitory way
[18,19].
Glutamate is thought of as the key mediator of excitotoxic
brain damage in, for example, cerebral ischemia or hypogly-
cemia [20]. Furthermore, disturbed glutamate transport has
been proposed to be associated with amyotrophic lateral scle-
rosis [21,22].
It has been shown that chronic opioid administration indu-
ces speci¢c plastic changes in the brain, which in some manner
counteract the processes underlying the acute actions of these
drugs [23]. Knowledge of the mechanisms underlying e¡ects
elicited upon chronic receptor agonist administration is only
fragmentary. We have previously shown that long-term opioid
receptor stimulation induces changes within the signal trans-
duction components in glial cells [23].
The present study was initiated in order to investigate
whether changes in GLT-1 expression could be induced within
astroglial cells in vitro as a result of long-term stimulation
with an excitatory (glutamate) and an inhibitory (N-opioid)
neurotransmitter. The results obtained may represent a glial
mechanism for preventing synaptic overexcitation in situa-
tions with elevated levels of extracellular glutamate, such as
epilepsy.
2. Materials and methods
2.1. Tissue culture
Primary glial cultures were prepared from newborn rat (Sprague-
Dawley) cerebral cortex (BpK Universal AB, Stockholm, Sweden).
The glial cells were grown in Dulbecco’s modi¢ed Eagle’s medium
(DME/high modi¢ed; Sera-Lab Ltd, Crawley Down, Sussex, UK)
supplemented with 250 000 IU/l penicillin; 0.5% streptomycin and
20% (v/v) fetal calf serum (Gibco, Bio-Cult. Labs., Ltd., London,
UK). The glial cells were grown in plastic Petri dishes (NUNC A/S,
Roskilde, Denmark) for 14 days, at which time the cultures became
con£uent and contained approximately 0.350 mg protein per culture
well. The cultures were characterized concerning the cellular compo-
sition and no neuronal cells were found using the present protocol
[12]. The medium (pH 7.3) was changed three times weekly and every
24 h during incubation of the astroglial cultures with the N-opioid
receptor agonist [D-Pen2, D-Pen5]-enkephalin (DPDPE, 1039^1035
M), glutamate (1039^1035 M) or potassium (7.5^56 mM). The neuro-
active substances were added to the experimental cultures at every
medium change, while control cultures received only fresh medium.
The treatments lasted for 48 h and were initiated so that all experi-
ments were terminated on day 14 in vitro.
2.2. Immunohistochemistry
Rabbit polyclonal antiserum against glial ¢brillary acidic protein
(GFAp; DAKO, Stockholm, Sweden) was used at a dilution of
1:100. Secondary £uorescein conjugated donkey anti-rabbit IgG
(Amersham) diluted 1:300 was used as a £uorescence label. The pri-
mary antiserum was tested at di¡erent dilutions. The speci¢city of the
staining obtained with the polyclonal rabbit GFAp antiserum was
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compared with the staining obtained using normal rabbit immuno-
globulins. Furthermore, the staining from incubations using only sec-
ondary antibodies was compared with the staining obtained after in-
cubation with both primary and secondary antibodies.
2.3. Drugs
L-Glutamate (Sigma, Stockholm, Sweden) was used as a glutamate
agonist. DPDPE (Sigma, Stockholm, Sweden) was used as a N-recep-
tor agonist. The doses used for DPDPE were based on previous ex-
periments [14].
2.4. cDNA
A sequence corresponding to bases 438^1023 of GLT-1 [4] was
subcloned from the base coordinates 398^985 of the GluT-1b cloned
by Roginski and coworkers [24] (GenBank accession number U15098)
into pBSK (Stratagene, La Jolla, CA, USA) and subsequently used to
generate synthetic standard mRNA and antisense probe. 35S-Labeled
RNA antisense probes were generated from linearized plasmids (NotI)
(Promega, Madison, WI, USA) using T7 (Promega, Madison, WI,
USA) polymerase. Synthetic standard was generated using (SacI)
(Promega, Madison, WI, USA) linearized plasmid and SP6 (Promega,
Madison, WI, USA) polymerase. The sense RNA was synthesized
essentially as previously described [25] and quanti¢ed spectrophoto-
metrically [26].
2.5. Northern blot
Total RNA was prepared essentially according to Chomczynski and
Sacchi [27] with the addition of a proteinase K (Boehringer
Mannheim, Bromma, Sweden) treatment. Brie£y, cultured astroglial
cells were scraped o¡ and immediately homogenized in 4 M guanidi-
nium thiocyanate. The homogenization solution was then diluted to
1 M guanidinium thiocyanate and proteinase K (1 mg/ml) was added.
These cells were digested at 37‡C for 45 min followed by phenol-
chloroform extraction. 15 Wg of total RNA was electrophoresed
through an agarose (1%)/formaldehyde (2.2 M) gel containing ethidi-
um bromide, transferred to Hybond-N (Amersham, Buckinghamshire,
UK) with a vacuum transfer system (LKB, Stockholm, Sweden) and
baked at 80‡C for 3 h. The membranes were prehybridized at 60‡C
for 12 h in 50% formamide, 25 mM H2NaPO4, 25 mM HNa2PO4,
5Ustandard saline citrate solution (SSC) (20USSC being 3 M NaCl,
0.3 M Na3-citrate, pH 7.4), 0.1% NaDodSO4 (SDS), 1 mM EDTA,
0.05% bovine serum albumin (BSA), 0.05% Ficoll, 0.05% polyvinyl-
pyrrolidone (PVP), 200 Wg/ml calf liver RNA, and 200 Wg/ml salmon
sperm DNA. Thereafter, hybridization was done in the prehybrid-
ization bu¡er for 18 h at 60‡C with the addition of 32P-labeled
RNA probe. The membranes were then washed in 0.1USSC and
0.1% SDS at 65‡C. Autoradiography was done using Kodak XAR-
5 ¢lm with intensifying screen (Eastman Kodak Co., Rochester, NY,
USA).
2.6. Quantitative analysis of GLT-1 transporter mRNA
An RNase protection hybridization assay was used to quantify
glutamate transporter mRNA. The solution hybridization RNase pro-
tection assay was performed essentially as described previously [23].
Brie£y, four or ¢ve preparations consisting of 10^15 cultures each
were used per agonist in each experiment, the cell material was
pooled, and total RNA was extracted, as described above. The hy-
bridization was done at 70‡C for 24 h in 0.06 M NaCl, 20 mM Tris-
HCl (pH 7.5), 4 mM EDTA, 0.1% NaDodSO4, 10 mM dithiothreitol
(DTT), 25% formamide, and 35S-labeled probes. 100 Wg herring sperm
DNA (Sigma) was added and, thereafter, the samples were treated
with 40 Wg/ml RNase A and 2 Wg/ml RNase T1 (Boehringer Mann-
heim, Bromma, Sweden). Protected radioactive probes were precipi-
tated with trichloroacetic acid, washed with ethanol, and collected on
glass-¢ber ¢lters (GF/C Whatman, Whatman International Ltd.,
Maidstone, UK) and measured for activity in a scintillation counter.
In order to visualize the hybridization of labeled probe to mRNA a
ribonuclease protection assay was performed using the RPA II kit
(Ambion Inc., Austin, TX, USA). Brie£y, samples of total cellular
RNA were hybridized overnight with 35S-labeled GLT-1 antisense
probe and then digested with RNase according to the instructions
provided by the manufacturer. The RNA:RNA hybrids were precipi-
tated, resuspended and separated on a 6% polyacrylamide/8 M urea
gel. The signal from the protected fragments was visualized using
autoradiography using Kodak XAR-5 ¢lm with intensifying screen
(Eastman Kodak Co., Rochester, NY, USA).
The amount of mRNA was calculated from a standard curve based
on hybridization to known amounts of synthetic sense RNA. The
total RNA content of the RNA preparations was analyzed spectro-
photometrically [26]. The integrity of all RNA preparations was
checked by electrophoresis in agarose (1%)/formaldehyde (2.2 M)
gels with ethidium bromide. The results are expressed as pg mRNA/
Wg total RNA.
2.7. Astroglial glutamate uptake
One hour before the experiments, the culture medium was changed
to serum-free Eagle’s medium. The experiments were done according
to Hansson and coworkers [9]. 1 WCi of 3H-labeled glutamate (20.1
Ci/mmol) together with unlabeled glutamate was added per ml incu-
bation medium to a ¢nal concentration range of 1037^1033 M (12
di¡erent concentrations). The cells were incubated for 4 min with the
3H-labeled solutions at 37‡C on a heated plate. Thereafter, the cul-
tures were immediately placed on ice and the medium was removed
rapidly by suction. Samples were taken for liquid scintillation count-
ing and excess radioactivity was removed by three rapid washes with
non-radioactive ice-cold medium containing 35 mM Tris-HCl (pH
7.4), 140 mM NaCl, 3 mM KCl, 2.5 mM MgCl2 and 20 mM glucose.
The cells were scraped o¡ and dissolved in 1 M NaOH, allowing
samples to be taken for measurement of radioactivity. Protein content
was measured according to Lowry et al. [28], with BSA as the stand-
ard.
The kinetic parameters Vmax and Km were then calculated using
Lineweaver-Burk plots [29,30]. The transport velocity (Vmax) of glu-
tamate into the cells is expressed as nmol/mg protein/min. The a⁄nity
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Fig. 1. Fluorescence micrograph of a representative astroglial culture consisting of type 1 astrocytes immunopositive for GFAp (green; FITC).
Nuclei are stained blue with DAPI. The bar represents 5 Wm.
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of glutamate for the glial glutamate transporters (Km) is expressed in
mM.
2.8. Statistical analyses
Statistical analyses were performed using one way analyses of var-
iance followed by Dunnett’s t-test.
3. Results
3.1. Culture protein
No statistically signi¢cant di¡erences in culture protein con-
tent were seen among the di¡erent treatment groups. The
control mean protein content was 0.396 þ 0.018 mg. All cul-
tures were inspected. No morphological di¡erences were noted
in any of the groups of cultures treated with opioids or glu-
tamate compared with control cultures.
3.2. Immunohistochemistry
Immunohistochemical analyses of the cultures showed a
homogeneous population of type 1 astroglial cells (GFAp
A2B53) (Fig. 1) with few type 2 astroglial cells (GFAp
A2B5) present in the cultures. Few non-astroglial cells
were seen in the cultures.
3.3. Quantitative analyses of GLT-1 mRNA after long-term
incubation
RNA extracted from astroglial primary cultures and ana-
lyzed by Northern blot with 32P-labeled rat glutamate trans-
porter cRNA probe revealed one major band with an esti-
mated size of 11 kbp (Fig. 2B) corresponding to the
reported size of the GLT-1 mRNA. The integrity and thus
the speci¢city of the protected RNA:RNA hybrid was visual-
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Fig. 3. Astroglial cultures were incubated with glutamate in concentrations of 1039, 1037 or 1035 M for 48 h. On day 14 in vitro, the cells
were harvested and the total RNA was extracted. RNA from approximately 10 cultures was pooled for each concentration. Quanti¢cation of
glutamate transporter GLT-1 mRNA was performed according to Section 2. The data represent the analysis of ¢ve di¡erent pooled prepara-
tions of RNA. *P6 0.05, **P6 0.01, ***P6 0.001.
Fig. 2. A: The integrity and thus the speci¢city of the protected RNA:RNA hybrid was visualized using the ribonuclease protection assay. The
result shows a major protected hybrid of 587 bp, corresponding to the size of the antisense GLT-1 probe used. Lane 1, size marker. Lane 2,
20 Wg total RNA. Lane 3, 10 Wg total RNA. Lane 4, 5 Wg total RNA. B: Total RNA was electrophoresed, transferred and hybridized with a
32P-labeled RNA probe under the conditions described in Section 2. One transcript with an estimated size of 11 kbp, corresponding to the
GLT-1 transporter mRNA, is seen. C: The abundance of GLT-1 mRNA was estimated with the solution hybridization RNase protection assay
and the amount of mRNA was calculated from a standard curve based on hybridization to known amounts of synthetic sense RNA.
T. Thorlin et al./FEBS Letters 425 (1998) 453^459 455
ized using the RPA II kit (Ambion Inc., Austin, TX, USA).
The result of RPA analysis showed a major protected hybrid
of 587 bp, corresponding to the size of the antisense GLT-1
probe used (Fig. 2A).
The abundance of GLT-1 mRNA was estimated with a
solution hybridization RNase protection assay and the
amount of mRNA was calculated from a standard curve
based on hybridization to known amounts of synthetic sense
RNA (Fig. 2C). The detection limit for the assay was 5 pg
GLT-1 mRNA. The intraassay coe⁄cient of variation was
6.88%. All samples were analyzed in the same assay.
Forty-eight hours of glutamate incubation resulted in a
dose-dependent increase in the abundance of GLT-1 mRNA
from 2.6 (control) to 4.25 pg GLT-1 mRNA/Wg RNA after
stimulation with 1039 M of glutamate (P6 0.05). Stimulation
with 1037 M of glutamate for 48 h resulted in an increase to
5.19 pg GLT-1 mRNA/Wg RNA (P6 0.01). Stimulation with
1035 M of glutamate for 48 h resulted in an increase to 6.20
pg GLT-1 mRNA/Wg RNA (P6 0.001) (Fig. 3). Opposing
e¡ects were seen after 48 h of N-opioid receptor stimulation.
This treatment resulted in a dose-dependent decrease in abun-
dance of glutamate transporter (Fig. 4). Forty-eight hours of
DPDPE incubation resulted in a dose-dependent decrease in
the abundance of GLT-1 mRNA from 2.6 (control) to 1.9 pg
GLT-1 mRNA/Wg RNA after stimulation with 1039 M of
DPDPE. Stimulation with 1037 M of DPDPE for 48 h re-
sulted in an decrease to 1.9 pg GLT-1 mRNA/Vg RNA
(P6 0.05). Stimulation with 1035 M of DPDPE for 48 h
resulted in an decrease to 1.5 pg GLT-1 mRNA/Wg RNA
(P6 0.01) (Fig. 4). We were unable to detect any statistically
signi¢cant e¡ects on the abundance of GLT-1 mRNA after
48 h of incubation with elevated levels of potassium in the
medium in the concentrations 7.5 mM, 12 mM and 56 mM
(Fig. 5).
3.4. Kinetics for astroglial glutamate uptake
The kinetic parameters Km and Vmax for the GLT-1 trans-
porter were determined in acute glutamate uptake experiments
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Fig. 5. Astroglial cultures were incubated with potassium 7.5, 12, or 56 mM for 48 h. On day 14 in vitro, the cells were harvested and the total
RNA was extracted. RNA from approximately 10 astroglial cultures was collected for each preparation. Quanti¢cation of glutamate transporter
GLT-1 mRNA was performed according to Section 2. The data represent the analysis of ¢ve di¡erent pooled preparations of RNA. No statis-
tically signi¢cant di¡erences in the abundance of GLT-1 mRNA were seen in cultures incubated with potassium compared with controls.
Fig. 4. Astroglial cultures were incubated with the selective N-opioid receptor agonist DPDPE in concentrations of 1039, 1037 or 1035 M for
48 h. On day 14 in vitro, the cells were harvested and the total RNA was extracted. RNA from approximately 10 astroglial cultures was col-
lected for each preparation. Quanti¢cation of glutamate transporter GLT-1 mRNA was performed according to Section 2. The data represent
the analysis of ¢ve di¡erent pooled preparations of RNA. *P6 0.05, **P6 0.01.
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in astroglial cultures after incubations with DPDPE, gluta-
mate or potassium. Astroglial cultures prepared from the rat
cerebral cortex were grown for 12 days and thereafter incu-
bated with the N-opioid receptor agonist DPDPE (1035 M) for
48 h. This treatment resulted in a decrease in Vmax and Km of
glutamate uptake compared with controls (P6 0.05) (Fig. 6).
Glutamate (1035 M) incubation for 48 h resulted in an in-
crease in Vmax of glutamate uptake compared with controls
(P6 0.05) (Fig. 6).
4. Discussion
The primary astroglial cultures used in the present study
have previously been characterized concerning cellular com-
position [12,31]. The presence of type 1 and type 2 astrocytes
was investigated. This astrocyte subclassi¢cation is based on
morphology and antigenic properties of cells in culture
[32,33]. The type 1 astrocytes have a £at polygonal morphol-
ogy and do not bind the A2B5 antibody, while the type 2
astrocytes bind the A2B5 antibody. Both type 1 and type 2
are GFAp positive. Only a small number of type 2 astrocytes
are present in the cultures.
Due to the lack of access to antibodies against the glial
speci¢c glutamate (GLT-1) transporter and the subsequent
inability to quantitate the transporter protein we decided to
quantify the uptake of [3H]glutamate into astroglial cells in
culture and in parallel experiments also measured the amounts
of GLT-1 mRNA. We consider the measurement of
[3H]glutamate uptake into astroglial cells a ‘functional’ assay.
The glutamate-mediated regulation of the GLT-1 mRNA
and uptake kinetics observed in this study might be mediated
via one or both of two major classes of glutamate receptors
generally recognized on astroglial cells : the metabotropic
(mGluR) or the ionotropic (iGluR) glutamate receptors [34^
36].
The DPDPE-mediated regulation of the glutamate trans-
porter mRNA and uptake kinetics observed in this study is
mediated via N-opioid receptors, one of the three major opioid
receptors besides W and U receptors. Subtypes of N-opioid
receptors have been proposed but not yet proven by molecular
cloning [37]. DPDPE used in the present study selectively
activates the N1 site. We and others have recently shown
that primary astrocytes from the cerebral cortex express N-
opioid receptors [14,16,38]. We have shown that antagoniz-
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Fig. 6. Astroglial cultures were incubated with the selective N-opioid receptor agonist DPDPE (1035 M) or glutamate (1035 M) for 48 h. On
day 14 in vitro, the kinetic parameters Km (mM) and Vmax (nmol/mg/min) were determined. Four separate experiments consisting of 12 cultures
were performed for each treatment and for the control group. S.E.M. values are given. *P6 0.05 vs. control.
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able N receptors inhibit the accumulation of cAMP upon stim-
ulation [38]. The second messenger responses elicited by stim-
ulation of glutamate receptors and N receptors share some
features, i.e. increased PIP2 hydrolysis and increased trans-
membrane Ca2 £ux, but also di¡er at signi¢cant points.
The opposing e¡ects on glutamate carrier mRNA and uptake
kinetics seen after glutamate receptor stimulation compared
with N receptor stimulation could re£ect di¡erences in the
complex signal transduction mechanisms involved in the re-
spective receptor second messenger cascade. Our results show
that glutamate and N-opioid receptors couple to the regulation
of glutamate transporter mRNA. One possibility could be
that the regulation of GLT-1 is cAMP-dependent, with
opioids decreasing the abundance via the known inhibition
of adenylyl cyclase and glutamate increasing the abundance
via cAMP induction through mGluRs. Prolonged N-opioid
receptor stimulation in astroglial cells increases the amount
of Gas mRNA and decreases the amount of Gai2 mRNA
[23], suggesting that these parts of the transduction system
might be involved in mediating the e¡ects observed after N
receptor stimulation and therefore might mediate the e¡ects
seen in the present study. This is in line with a recent study
showing that the expression of GLT-1 was increased by ele-
vation of cAMP while GLAST was constitutively expressed
[39].
The results of Swanson and co-workers [39] might suggest
that the decrease in a⁄nity (Km) seen after N-opioid receptor
stimulation might re£ect the a⁄nity for GLAST rather than
GLT-1 and that the increase in Vmax seen after glutamate
re£ects an increase in GLT-1 uptake capacity in the present
study. The decrease in abundance of GLT-1 mRNA after
DPDPE incubation might re£ect the general inhibitory nature
of opioid signaling in the central nervous system. Long-stand-
ing opioid-mediated synaptic depression might induce a de-
crease in e.g. glutamate neurotransmission. This possibility
could make an opioid-mediated down-regulation of glutamate
uptake a physiological adaptation of synaptic glutamate
transmission. Such a mechanism might also contribute to
the increased excitability associated with opioid abstinence
after long-term opioid administration.
Glutamatergic denervation has previously been shown to
down-regulate GLT-1 expression, suggesting a glutamate re-
ceptor-mediated regulation [40]. It is tempting to speculate
that the increased abundance of GLT-1 mRNA and Vmax
after glutamate receptor stimulation re£ect compensatory
mechanisms aiming at the protection of the central nervous
system against e.g. excitotoxicity. Considering this, it seems
functional to up-regulate the astroglial uptake capacity for
glutamate in order to ameliorate or prevent further excitotoxic
damage in synaptic areas with increased glutamate transmis-
sion.
No alterations were seen in the abundance of GLT-1
mRNA after prolonged depolarization of the glial cells. One
possible explanation for this might be that more long-standing
di¡erences in glial membrane potential might be physiological,
as compared to long-standing alterations in synaptic neuro-
transmitters such as glutamate and opioids. One must also
consider the lack of speci¢city of a long-standing membrane
depolarization, which might be one explanation for why the
central nervous system seems unable to adapt or quench seiz-
ure frequency in epileptic disorders.
Glutamate receptor-induced changes in glial glutamate up-
take systems may be an endogenous mechanism for prevent-
ing synaptic overexcitation in situations with elevated levels of
extracellular glutamate, such as ischemia, and might also be
associated with the paradoxical neuroprotective e¡ects of
transient ischemia prior to a prolonged ischemic insult [41].
Apparently, a coupling also seems to exist between astro-
glial receptors and the uptake of glutamate, although this is
only indirectly shown in this study. This coupling is interest-
ing, since it suggests that the transport of glutamate can be
regulated by the presence of a transmitter and, therefore,
might be of pharmacological relevance.
Manipulation of astroglial glutamate uptake during massive
extracellular glutamate load might provide novel neuroprotec-
tive strategies.
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